News – Page 1115 – Endpoints News

Array shares surge as second chapter of its PhIII cancer combo story ends on an upbeat note

9 years ago

Merck increases grip on its lead in lung cancer, winning approval for Keytruda/chemo combo as first-line therapy

9 years ago

Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal

9 years ago

From Biogen’s buy side to biotech CEO: Josh Mandel-Brehm joins the Polaris family as a serial entrepreneur in the ...

9 years ago

As M&A buzz heats up, Parexel plans 1,200 layoffs; Grünenthal is hiring for its new Boston/Cambridge center

9 years ago

New study points to a double-digit hike in branded drug prices, spotlighting a growing national debate

9 years ago

AstraZeneca’s PhIII bid on asthma drug tralokinumab flops, and that’s no surprise

9 years ago

In a stunning setback, Roche says its top cancer drug Tecentriq failed a key PhIII study

9 years ago

Scoop: Turing is considering a $100M cash offer for the drug that triggered a national scandal over drug pricing

9 years ago

It’s official: Senate confirms Scott Gottlieb as the country’s next FDA commissioner

9 years ago

PhRMA drums out 22 members who didn’t make the cut as major league R&D players

9 years ago

Synergy Pharma preps step 2 for Trulance as positive PhIII IBS-C data squares off against Ironwood and Ardelyx

9 years ago

Scott Gottlieb clears another hurdle in last stretch ahead of the FDA; Sanofi inks €250M bispecific discovery deal ...

9 years ago

Recro Pharma tees up an NDA for its COX-2 pain drug following positive PhIII program

9 years ago

After Kite Pharma stuns analysts with news of a death in lead CAR-T study, safety questions sour launch forecast

9 years ago

Sanofi takes its own drug pricing pledge, pointing to a decline in their aggregate net price

9 years ago

Takeda, Abingworth provide a $100M bankroll for an upstart T cell player, building in a buyout option

9 years ago

Was PTC Therapeutics playing games when it tried to defuse the deflazacort controversy with a $35,000 annual price?

9 years ago

Can PTC get away with a $35,000 price tag on a cheap, old overseas steroid for Duchenne?

9 years ago

Abraxis vet Neil Desai gets Celgene backing for $23M A round; Two more biotechs set IPO terms

9 years ago

One of Kite Pharma’s CAR-T patients died from cerebral edema, triggering a safety alarm

9 years ago

Nixed by the FDA, TherapeuticsMD is now planning a long-shot bid to reverse the decision

9 years ago

OncoMed racks up three straight clinical disasters as lead drug implodes

9 years ago

Building an orphan pipeline, Horizon Pharma bags PhIII-ready rare disease drug in $145M buyout

9 years ago

First page Previous page 1112 1113 111411151116 1117 1118 Next page Last page